Latest & greatest articles for lung cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lung cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on lung cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for lung cancer

61. Research on the value of the T cell spot test for tuberculosis for the diagnosis of lung cancer combined with pulmonary tuberculosis

Research on the value of the T cell spot test for tuberculosis for the diagnosis of lung cancer combined with pulmonary tuberculosis 30079988 2018 11 14 1759-7714 9 10 2018 Oct Thoracic cancer Thorac Cancer Research on the value of the T cell spot test for tuberculosis for the diagnosis of lung cancer combined with pulmonary tuberculosis. 1231-1234 10.1111/1759-7714.12816 This study was conducted to investigate the value of the T cell spot test for tuberculosis (T-SPOT.TB) for the diagnosis (...) of patients with lung cancer combined with pulmonary tuberculosis (LCTB). Thirty-six patients diagnosed with LCTB who received treatment at Shandong Provincial Chest Hospital from September 2014 to 2017 were randomly chosen and enrolled as an observation group; 63 patients diagnosed with LC alone in the same period were included as the control. The T-SPOT.TB results of the two groups were compared. The positive rate of T-SPOT.TB in 36 patients with LCTB was 88.9% (32/36), and in 63 patients with LC

Thoracic cancer2018 Full Text: Link to full Text with Trip Pro

62. Surgically treated lung cancer patients: do they all smoke and would they all have been detected with lung cancer screening?

Surgically treated lung cancer patients: do they all smoke and would they all have been detected with lung cancer screening? 30083553 2018 11 14 2312-0541 4 3 2018 Jul ERJ open research ERJ Open Res Surgically treated lung cancer patients: do they all smoke and would they all have been detected with lung cancer screening? 00001-2018 10.1183/23120541.00001-2018 Since publication of the National Lung Cancer Screening Trial (NLST) results early lung cancer detection has been widely studied (...) , targeting individuals based on smoking history and age. However, over recent decades several changes in lung cancer epidemiology, including risk factors, have taken place. The aim of the current study was to explore smoking prevalence among lung cancer patients who had been treated surgically or undergone a diagnostic operation and whether these patients would have met the NLST inclusion criteria. All patients operated on for lung cancer in a university hospital in Estonia between 2009 and 2015 were

ERJ open research2018 Full Text: Link to full Text with Trip Pro

63. Correlation between radiomic features based on contrast‐enhanced computed tomography images and Ki‐67 proliferation index in lung cancer: A preliminary study

Correlation between radiomic features based on contrast‐enhanced computed tomography images and Ki‐67 proliferation index in lung cancer: A preliminary study 30070037 2018 11 14 1759-7714 9 10 2018 Oct Thoracic cancer Thorac Cancer Correlation between radiomic features based on contrast-enhanced computed tomography images and Ki-67 proliferation index in lung cancer: A preliminary study. 1235-1240 10.1111/1759-7714.12821 The purpose of the study was to investigate the association between (...) radiomic features based on contrast-enhanced multidetector computed tomography (CT) and the Ki-67 proliferation index (PI) in patients with lung cancer. One hundred and ten patients with lung cancer confirmed by surgical histology were retrospectively included. Radiomic features were extracted from preoperative contrast-enhanced chest multidetector CT images for each tumor using open-source three-dimensional Slicer software. Statistical analysis was performed to determine significant radiomic features

Thoracic cancer2018 Full Text: Link to full Text with Trip Pro

64. Prophylactic Cranial Irradiation Versus Observation in Radically Treated Stage III Non-Small-Cell Lung Cancer: A Randomized Phase III NVALT-11/DLCRG-02 Study

Prophylactic Cranial Irradiation Versus Observation in Radically Treated Stage III Non-Small-Cell Lung Cancer: A Randomized Phase III NVALT-11/DLCRG-02 Study 29787357 2018 08 07 1527-7755 36 23 2018 Aug 10 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Prophylactic Cranial Irradiation Versus Observation in Radically Treated Stage III Non-Small-Cell Lung Cancer: A Randomized Phase III NVALT-11/DLCRG-02 Study. 2366-2377 10.1200/JCO (...) .2017.77.5817 Purpose The purpose of the current study was to investigate whether prophylactic cranial irradiation (PCI) reduces the incidence of symptomatic brain metastases in patients with stage III non-small-cell lung cancer (NSCLC) treated with curative intention. Patients and Methods Patients with stage III NSCLC-staged with a contrast-enhanced brain computed tomography or magnetic resonance imaging-were randomly assigned to either observation or PCI after concurrent/sequential chemoradiotherapy

EvidenceUpdates2018

65. Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer

Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer 29768118 2018 07 27 1527-7755 36 22 2018 Aug 01 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer. 2251-2258 10.1200/JCO.2017.77.4794 Purpose (...) The phase III PROFILE 1014 trial compared crizotinib with chemotherapy as first-line treatment in patients with anaplastic lymphoma kinase (ALK) -positive advanced nonsquamous non-small-cell lung cancer. Here, we report the final overall survival (OS) results. Patients and Methods Patients were randomly assigned to receive oral crizotinib 250 mg twice daily (n = 172) or intravenous pemetrexed 500 mg/m 2 plus cisplatin 75 mg/m 2 or carboplatin (area under the concentration-time curve of 5 to 6 mg·mL/min

EvidenceUpdates2018

66. Lung cancer

Lung cancer Top results for lung cancer - Trip Database or use your Google+ account Turning Research Into Practice My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box (...) and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for lung cancer The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical

Trip Latest and Greatest2018

67. Incorporating Coexisting Chronic Illness into Lung Cancer Screening: A Research Statement

Incorporating Coexisting Chronic Illness into Lung Cancer Screening: A Research Statement AMERICANTHORACICSOCIETY DOCUMENTS IncorporatingCoexisting ChronicIllness into Decisionsabout Patient Selection for LungCancer Screening An Of?cial American Thoracic Society Research Statement M. Patricia Rivera, Nichole T. Tanner, Gerard A. Silvestri, Frank C. Detterbeck, Martin C. Tammem¨ agi, Robert P. Young, Christopher G. Slatore, Tanner J. Caverly, Cynthia M. Boyd, Dejana Braithwaite, Joelle T. Fathi (...) -makingwithpatientswhomaynot bene?tfromLCSowingtocoexistingchronicillness.Thisstatement establishesaresearchframeworktoaddressessentialquestions regarding how toincorporateand communicaterisks of comorbiditiesintopatientselectionanddecisionsregardingLCS. Keywords: lung cancer screening; comorbidities; communication of risk Contents Overview Key Conclusions and Recommendations Introduction Methods Results Juxtaposing Lung Cancer Risk and Competing Risk of Death from Other Causes COPD, Lung Cancer Risk, Competing Risk

American Thoracic Society2018

68. Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer

Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer P Pembrolizumab for untreated PD- embrolizumab for untreated PD- L1-positiv L1-positive metastatic non-small-cell e metastatic non-small-cell lung cancer lung cancer T echnology appraisal guidance Published: 18 July 2018 nice.org.uk/guidance/ta531 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility (...) equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer (TA531) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2

National Institute for Health and Clinical Excellence - Technology Appraisals2018

69. Alectinib hydrochloride (Alecensa) - anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC)

Alectinib hydrochloride (Alecensa) - anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) 1 alectinib 150mg hard capsules (Alecensa ® ) SMC2012 Roche Products Limited 6 July 2018 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows: ADVICE: following a full submission assessed under (...) the orphan medicine process alectinib (Alecensa ® ) is accepted for use within NHS Scotland. Indication under review: as monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). Alectinib, compared with another tyrosine kinase inhibitor, significantly improved progression-free survival in treatment-naïve adults with advanced or recurrent ALK-positive NSCLC. This SMC advice takes account of the benefits

Scottish Medicines Consortium2018

70. Alectinib for untreated ALK-positive advanced non-small-cell lung cancer

Alectinib for untreated ALK-positive advanced non-small-cell lung cancer Alectinib for untreated ALK Alectinib for untreated ALK-positiv -positive e advanced non-small-cell lung cancer advanced non-small-cell lung cancer T echnology appraisal guidance Published: 8 August 2018 nice.org.uk/guidance/ta536 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations (...) and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Alectinib for untreated ALK-positive advanced non-small-cell lung cancer (TA536) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 24Contents Contents 1

National Institute for Health and Clinical Excellence - Technology Appraisals2018

71. Tobacco Dependence Predicts Higher Lung Cancer and Mortality Rates and Lower Rates of Smoking Cessation in the National Lung Screening Trial

Tobacco Dependence Predicts Higher Lung Cancer and Mortality Rates and Lower Rates of Smoking Cessation in the National Lung Screening Trial 29793736 2018 07 25 1931-3543 154 1 2018 Jul Chest Chest Tobacco Dependence Predicts Higher Lung Cancer and Mortality Rates and Lower Rates of Smoking Cessation in the National Lung Screening Trial. 110-118 S0012-3692(18)30587-7 10.1016/j.chest.2018.04.016 Incorporating tobacco treatment within lung cancer screening programs has the potential to influence (...) performed. Clinical outcomes (smoking cessation, lung cancer, and mortality) were assessed with descriptive statistics and χ 2 tests stratified according to nicotine dependence. Logistic and Cox regression models were used to study the influence of dependence on smoking cessation and mortality, respectively. Patients with high dependence scores were less likely to quit smoking compared with low dependence smokers (TTFC OR, 0.50 [95% CI, 0.42-0.60]). Indicators of high dependence, as measured according

EvidenceUpdates2018

72. Analysis of topoisomerase I expression and identification of predictive markers for efficacy of topotecan chemotherapy in small cell lung cancer

Analysis of topoisomerase I expression and identification of predictive markers for efficacy of topotecan chemotherapy in small cell lung cancer 30058109 2018 11 14 1759-7714 9 9 2018 Sep Thoracic cancer Thorac Cancer Analysis of topoisomerase I expression and identification of predictive markers for efficacy of topotecan chemotherapy in small cell lung cancer. 1166-1173 10.1111/1759-7714.12819 We evaluated topoisomerase I (TOPO1) expression in patients with small cell lung cancer (SCLC (...) chemotherapy had better survival than refractory patients who received second-line topotecan chemotherapy. © 2018 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. Lv Chunxin C Geriatric Department, Minhang Hospital, Fudan University, Shanghai, China. Liu Xiuju X Department of Medical Oncology, Shandong Cancer Hospital and Institute, Jinan, China. Zheng Qiwen Q Department of Epidemiology and Biostatistics, School of Public Health, Peking University

Thoracic cancer2018 Full Text: Link to full Text with Trip Pro

73. Overexpression of S100A13 protein is associated with tumor angiogenesis and poor survival in patients with early‐stage non‐small cell lung cancer

Overexpression of S100A13 protein is associated with tumor angiogenesis and poor survival in patients with early‐stage non‐small cell lung cancer 30047626 2018 11 14 1759-7714 9 9 2018 Sep Thoracic cancer Thorac Cancer Overexpression of S100A13 protein is associated with tumor angiogenesis and poor survival in patients with early-stage non-small cell lung cancer. 1136-1144 10.1111/1759-7714.12797 S100A13 plays a key role in tumor growth and metastasis. The purpose of this study (...) was to investigate the prognostic significance of S100A13 expression, microvessel density (MVD), and survival in early stage non-small cell lung cancer (NSCLC). In silico analysis was performed to determine the associations between S100A13 and NSCLC. The data of 82 patients with early-stage NSCLC who underwent radical resection were evaluated. Paraffin-embedded tumor specimens were stained with S100A13 and CD31 (a specific endothelial marker) using immunohistochemical methods. Prognostic significance

Thoracic cancer2018 Full Text: Link to full Text with Trip Pro

74. Stereotactic Body Radiation Therapy for Biopsy-Proven Primary Non–Small-Cell Lung Cancer: Experience of Patients With Inoperable Cancer at a Single Brazilian Institution

Stereotactic Body Radiation Therapy for Biopsy-Proven Primary Non–Small-Cell Lung Cancer: Experience of Patients With Inoperable Cancer at a Single Brazilian Institution 30085881 2018 12 07 2378-9506 4 2018 Jul Journal of global oncology J Glob Oncol Stereotactic Body Radiation Therapy for Biopsy-Proven Primary Non-Small-Cell Lung Cancer: Experience of Patients With Inoperable Cancer at a Single Brazilian Institution. 1-8 10.1200/JGO.18.00020 Purpose Stereotactic body radiation therapy (SBRT (...) ) has emerged as a treatment option for patients with non-small-cell lung cancer (NSCLC). We report the clinical outcomes and toxicity for patients with inoperable primary NSCLC treated with SBRT. Methods Between 2007 and 2015, 102 consecutive lung lesions were treated with SBRT at our center, of which 59 primary NSCLC lesions (from 54 patients with inoperable disease) were retrospectively reviewed (43 lesions were excluded because of metastases or because there was no biopsy specimen). We report

Journal of global oncology2018 Full Text: Link to full Text with Trip Pro

75. Low-dose nivolumab can be effective in non-small cell lung cancer: alternative option for financial toxicity

Low-dose nivolumab can be effective in non-small cell lung cancer: alternative option for financial toxicity 30094065 2018 11 14 2059-7029 3 5 2018 ESMO open ESMO Open Low-dose nivolumab can be effective in non-small cell lung cancer: alternative option for financial toxicity. e000332 10.1136/esmoopen-2018-000332 Nivolumab is used at 3 mg/kg or fixed doses of 240 mg every 2 weeks. There was no dose-response/toxicity relationship of nivolumab. This study evaluated the efficacy of low-dose (...) nivolumab as an alternative to the financial toxicity of standard-dose nivolumab in treatment of non-small cell lung cancer (NSCLC). Outcomes of patients with NSCLC treated with nivolumab as a routine practice at two tertiary hospitals in Korea were retrospectively analysed. Patients who could not afford standard nivolumab treatment received low-dose nivolumab (20 or 100 mg fixed dose every 3 weeks). Others received standard dose of 3 mg/kg every 2 weeks. Progression-free survival (PFS) and overall

ESMO open2018 Full Text: Link to full Text with Trip Pro

76. CSF-1 and Ang-2 serum levels — prognostic and diagnostic partners in non-small cell lung cancer

CSF-1 and Ang-2 serum levels — prognostic and diagnostic partners in non-small cell lung cancer 30094067 2018 11 14 2059-7029 3 5 2018 ESMO open ESMO Open CSF-1 and Ang-2 serum levels - prognostic and diagnostic partners in non-small cell lung cancer. e000349 10.1136/esmoopen-2018-000349 Lung cancer is the most incident and lethal form of cancer, with late diagnosis as a major determinant of its bad prognosis. Immunotherapies targeting immune checkpoints improve survival, but positive results (...) encompass only 30%-40% of the patients, possibly due to alternative pathways to immunosuppression, including tumour-associated macrophages (TAM). Colony stimulating factor-1 (CSF-1) is implicated in TAM differentiation and recruitment to tumours and in tumour angiogenesis, through a special setting of Tie-2-expressing macrophages, which respond to angiopoietin-2 (Ang-2). We evaluated the role of serum levels of CSF-1 in non-small cell lung cancer (NSCLC) prognosis and whether these could serve

ESMO open2018 Full Text: Link to full Text with Trip Pro

77. Phase II study assessing the benefit of cisplatin re-introduction (stop-and-go strategy) in patients with advanced non-squamous non-small cell lung cancer: the IFCT-1102 BUCiL study (a Better Use of Cisplatin in Lung cancer)

Phase II study assessing the benefit of cisplatin re-introduction (stop-and-go strategy) in patients with advanced non-squamous non-small cell lung cancer: the IFCT-1102 BUCiL study (a Better Use of Cisplatin in Lung cancer) 30094074 2018 11 14 2059-7029 3 5 2018 ESMO open ESMO Open Phase II study assessing the benefit of cisplatin re-introduction (stop-and-go strategy) in patients with advanced non-squamous non-small cell lung cancer: the IFCT-1102 BUCiL study (a Better Use of Cisplatin (...) in Lung cancer). e000394 10.1136/esmoopen-2018-000394 This single-arm phase II trial aimed to evaluate a stop-and-go strategy with cisplatin-based chemotherapy and bevacizumab in advanced non-squamous non-small cell lung cancer (NSCLC). Patients were initially treated with three cycles of pemetrexed, cisplatin plus bevacizumab (sequence 1) followed by bevacizumab maintenance and after progression, re-introduction of three cycles of pemetrexed, cisplatin plus bevacizumab (sequence 2) and pemetrexed

ESMO open2018 Full Text: Link to full Text with Trip Pro

78. Patient-reported outcomes in a phase II, North American study of alectinib in patients with ALK-positive, crizotinib-resistant, non-small cell lung cancer

Patient-reported outcomes in a phase II, North American study of alectinib in patients with ALK-positive, crizotinib-resistant, non-small cell lung cancer 30018815 2018 11 14 2059-7029 3 5 2018 ESMO open ESMO Open Patient-reported outcomes in a phase II, North American study of alectinib in patients with ALK -positive, crizotinib-resistant, non-small cell lung cancer. e000364 10.1136/esmoopen-2018-000364 In a phase II North American study (NP28761; NCT01871805), the anaplastic lymphoma kinase (...) (ALK) inhibitor alectinib demonstrated both systemic and central nervous system (CNS) efficacy with good tolerability in patients with ALK -positive non-small cell lung cancer. We describe patient-reported outcomes (PROs) from the NP28761 study. PROs and health-related quality of life (HRQoL) benefits were assessed using two self-administered questionnaires (the European Organisation for Research and Treatment of Cancer 30-Item Quality of Life Questionnaire-Core (EORTC QLQ-C30), and the 13-item

ESMO open2018 Full Text: Link to full Text with Trip Pro

79. Correlation between progression‐free survival, tumor burden, and circulating tumor DNA in the initial diagnosis of advanced‐stage EGFR‐mutated non‐small cell lung cancer

Correlation between progression‐free survival, tumor burden, and circulating tumor DNA in the initial diagnosis of advanced‐stage EGFR‐mutated non‐small cell lung cancer 29989342 2018 11 14 1759-7714 9 9 2018 Sep Thoracic cancer Thorac Cancer Correlation between progression-free survival, tumor burden, and circulating tumor DNA in the initial diagnosis of advanced-stage EGFR-mutated non-small cell lung cancer. 1104-1110 10.1111/1759-7714.12793 This study was conducted to identify (...) ctDNA. Tumor burden may be associated with plasma ctDNA detection. A shorter PFS was associated with detection of ctDNA and extra-thoracic lymph node metastasis. Dynamic changes in the ctDNA level may help predict clinical outcomes. © 2018 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. Lee Yunkyoung Y http://orcid.org/0000-0001-7364-5609 Department of Pulmonary and Critical Care Medicine, Chungnam National University Hospital, Daejeon, South

Thoracic cancer2018 Full Text: Link to full Text with Trip Pro

80. Heterogeneous responses and resistant mechanisms to crizotinib in ALK‐positive advanced non‐small cell lung cancer

Heterogeneous responses and resistant mechanisms to crizotinib in ALK‐positive advanced non‐small cell lung cancer 29978950 2018 11 14 1759-7714 9 9 2018 Sep Thoracic cancer Thorac Cancer Heterogeneous responses and resistant mechanisms to crizotinib in ALK-positive advanced non-small cell lung cancer. 1093-1103 10.1111/1759-7714.12791 ALK-tyrosine kinase inhibitors (TKIs) have been proven effective for treating ALK-positive non-small cell lung cancer (NSCLC), although patients present (...) been identified and correlate to diverse responses to crizotinib. Comprehensive and dynamic mutation profiling is required to better predict clinical outcomes. © 2018 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. Kang Jin J Guangdong Cardiovascular Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China. Division of Pulmonary Oncology, Guangdong Lung Cancer Institute, Guangdong General Hospital

Thoracic cancer2018 Full Text: Link to full Text with Trip Pro